Hyperglycemia News and Research

RSS
Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Combination of perifosine and temsirolimus shows promise against malignant glioma

Combination of perifosine and temsirolimus shows promise against malignant glioma

Combination of hormones may effectively treat obesity with few side effects

Combination of hormones may effectively treat obesity with few side effects

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

New article asserts concerns about revisions to gestational diabetes diagnostic criteria

New article asserts concerns about revisions to gestational diabetes diagnostic criteria

FDA accepts Sunovion’s two LATUDA sNDAs for review

FDA accepts Sunovion’s two LATUDA sNDAs for review

HbA1c equally useful across ethnic groups

HbA1c equally useful across ethnic groups

HbA1c equally useful across ethnic groups

HbA1c equally useful across ethnic groups

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Intensive glycemic control does not reduce mortality in neurocritical care patients

Intensive glycemic control does not reduce mortality in neurocritical care patients

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

Tight glycemic control does not reduce infection rate after pediatric cardiac surgery

Tight glycemic control does not reduce infection rate after pediatric cardiac surgery

Obese adults with excess visceral fat, biomarkers of insulin resistance more likely to develop diabetes

Obese adults with excess visceral fat, biomarkers of insulin resistance more likely to develop diabetes

Age at diabetes onset linked to macular edema onset

Age at diabetes onset linked to macular edema onset

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Three alternative diabetes markers found

Three alternative diabetes markers found

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Statins: cardiovascular benefits outweigh diabetes risk

Statins: cardiovascular benefits outweigh diabetes risk

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.